Inozyme Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Inozyme Pharma
INZY Stock  USD 0.97  0.05  4.90%   
Inozyme Pharma financial statements provide useful quarterly and yearly information to potential Inozyme Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Inozyme Pharma financial statements helps investors assess Inozyme Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Inozyme Pharma's valuation are summarized below:
Market Capitalization
65.5 M
Earnings Share
(1.62)
We have found one hundred twenty available fundamental trends for Inozyme Pharma, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Inozyme Pharma regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 252.9 M in 2025. Enterprise Value is likely to rise to about 211.1 M in 2025
Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 1.6 M, Interest Income of 8 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.16. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.
  
Check out the analysis of Inozyme Pharma Correlation against competitors.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Inozyme Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets133.2 M123.2 M83.1 M
Slightly volatile
Other Current Liabilities9 M16 M4.9 M
Slightly volatile
Total Current Liabilities35.6 M33.9 M9.1 M
Slightly volatile
Property Plant And Equipment Net2.4 M1.3 M1.2 M
Slightly volatile
Accounts Payable2.1 M2.5 M1.5 M
Slightly volatile
Cash38.8 M21.1 M41.6 M
Very volatile
Non Current Assets Total2.4 M2.5 M2.9 M
Slightly volatile
Non Currrent Assets Other2.2 M1.2 M1 M
Slightly volatile
Other Assets5.4 M4.3 M2.3 M
Slightly volatile
Cash And Short Term Investments124.4 M113.1 M78.8 M
Slightly volatile
Net Receivables464.9 K442.8 K125.5 K
Slightly volatile
Common Stock Shares Outstanding36.1 M62.8 M24.2 M
Slightly volatile
Short Term Investments89.9 M92 M45 M
Slightly volatile
Liabilities And Stockholders Equity133.2 M123.2 M83.1 M
Slightly volatile
Non Current Liabilities Total25.2 M31.5 M42.8 M
Slightly volatile
Capital Surpluse402.5 M383.4 M123.1 M
Slightly volatile
Other Current Assets4 M7.6 M1.9 M
Slightly volatile
Total Liabilities35.5 M65.4 M50.3 M
Slightly volatile
Deferred Long Term Liabilities49.5 K64.4 K43.7 K
Slightly volatile
Total Current Assets126.6 M120.7 M79.9 M
Slightly volatile
Net Working Capital112.3 M86.8 M72.1 M
Slightly volatile
Common Stock3.5 K6.9 K2.1 K
Slightly volatile
Property Plant Equipment2.1 M2.3 M1.1 M
Slightly volatile
Property Plant And Equipment Gross4.3 M4.5 M2 M
Slightly volatile
Short and Long Term Debt Total16.2 M15.4 M6.4 M
Slightly volatile
Other Liabilities1 M1.2 M1.3 M
Slightly volatile
Current Deferred Revenue2.2 M4.4 M1.3 M
Slightly volatile
Common Stock Total Equity2.9 K4.6 K2.5 K
Slightly volatile
Capital Lease Obligations1.6 M913 K1.5 M
Slightly volatile
Non Current Liabilities Other2.2 M2.2 M1.6 M
Slightly volatile
Short Term Debt16.2 M15.4 M2.4 M
Slightly volatile
Long Term Debt29.5 M31.5 M10 M
Slightly volatile
Long Term Debt Total3.3 M3.7 M4.1 M
Slightly volatile
Short and Long Term Debt11.6 M13.1 M14.2 M
Slightly volatile

Inozyme Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income1.6 M2.1 M871.1 K
Slightly volatile
Interest Income8 M7.7 M1.6 M
Slightly volatile
Depreciation And Amortization541.8 K958 K291.4 K
Slightly volatile
Selling General Administrative15.7 M20.8 M9 M
Slightly volatile
Other Operating Expenses53.2 M87 M32.7 M
Slightly volatile
Research Development46.1 M83.2 M25.3 M
Slightly volatile
Total Operating Expenses62 M104 M34.3 M
Slightly volatile
Reconciled Depreciation519.8 K742 K252.2 K
Slightly volatile
Total Other Income Expense Net2.2 M2 M3.2 M
Slightly volatile
Cost Of Revenue841.1 K1.5 M431.2 K
Slightly volatile
Non Operating Income Net Other1.7 M1.6 M808.9 K
Slightly volatile
Selling And Marketing Expenses395.2 K444.6 K484.7 K
Slightly volatile

Inozyme Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock266.9 K281 K28.9 M
Pretty Stable
Stock Based Compensation5.2 M7.9 M2.6 M
Slightly volatile
Begin Period Cash Flow30.2 M34.9 M16.1 M
Slightly volatile
Other Cashflows From Financing Activities833.1 K877 K21 M
Slightly volatile
Depreciation521.6 K742 K253 K
Slightly volatile
Capital Expenditures58.9 K62 K266.5 K
Very volatile
Total Cash From Financing Activities10.8 M11.4 M42.6 M
Pretty Stable
End Period Cash Flow23.9 M21.4 M32.6 M
Slightly volatile
Exchange Rate Changes19.2 K21.6 K23.6 K
Slightly volatile
Net Borrowings3.2 M3.6 M4 M
Slightly volatile
Dividends Paid24.4 M46.4 M10.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.07940.08365.9754
Slightly volatile
Payables Turnover1.051.00.2789
Slightly volatile
Cash Per Share1.711.80043.5004
Pretty Stable
Days Payables Outstanding3593788.5 K
Slightly volatile
Income Quality1.030.90081.1514
Slightly volatile
Current Ratio3.383.5614.4969
Slightly volatile
Debt To Equity0.280.26660.066
Slightly volatile
Capex Per Share9.0E-40.0010.0139
Slightly volatile
Interest Debt Per Share0.240.15690.143
Slightly volatile
Debt To Assets0.07050.12510.0367
Slightly volatile
Days Of Payables Outstanding3593788.5 K
Slightly volatile
Ebt Per Ebit0.740.98070.7488
Slightly volatile
Long Term Debt To Capitalization0.110.220.0631
Slightly volatile
Total Debt To Capitalization0.220.21050.0533
Slightly volatile
Debt Equity Ratio0.280.26660.066
Slightly volatile
Quick Ratio3.383.5614.5752
Slightly volatile
Net Income Per E B T0.780.880.9398
Slightly volatile
Cash Ratio0.590.621910.5688
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00071.025
Very volatile
Debt Ratio0.07050.12510.0367
Slightly volatile

Inozyme Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap252.9 M174 M249.1 M
Slightly volatile
Enterprise Value211.1 M168.3 M211.9 M
Slightly volatile

Inozyme Fundamental Market Drivers

Cash And Short Term Investments113.1 M

Inozyme Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.4 M2.2 M
Cost Of Revenue1.5 M841.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY